Trials / Completed
CompletedNCT02536404
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 118 (actual)
- Sponsor
- Arena Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether etrasimod (APD334) is a safe and effective treatment for ulcerative colitis after 52 weeks of treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Etrasimod | |
| DRUG | Placebo |
Timeline
- Start date
- 2016-01-25
- Primary completion
- 2018-11-01
- Completion
- 2018-11-01
- First posted
- 2015-08-31
- Last updated
- 2021-11-26
- Results posted
- 2021-11-26
Locations
127 sites across 21 countries: United States, Australia, Austria, Belgium, Bulgaria, Canada, Czechia, France, Germany, Hungary, Israel, Latvia, Lithuania, New Zealand, Poland, Romania, Russia, South Korea, Spain, Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT02536404. Inclusion in this directory is not an endorsement.